Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336089 | 0.80 | CYP3A4 (0.53) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL4649487 | 0.75 | CYP3A4 (0.76) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL133421 | 0.75 | MAOA (0.57) | CYP3A4ALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL15668077 | 0.74 | CYP3A4 (0.57) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL30343626 | 0.74 | CYP3A4 (0.57) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL6617327 | 0.71 | MAPT (0.60) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL30233473 | 0.71 | MAPT (0.60) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL21683096 | 0.71 | CYP3A4 (0.54) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL15668055 | 0.71 | CYP3A4 (0.60) | CYP3A4CYP2C19ALDH1A1HPGDMAPT | |
| SCHEMBL19097304 | 0.69 | ALDH1A1 (0.68) | CYP3A4CYP2C19ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592143-B2 | Methods of treating diseases responsive to induction of apoptosis and screening assays | CYTOVIA, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1620564-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1620564-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094647-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | HEATR6, HEATR1, AIP | CYP3A4 4498/4885CYP2C19 4760/4885ALDH1A1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.